JUL 31, 2026 · PHASE 2 TRIAL
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
ClinicalTrials.gov
This is a recruiting Phase 2 trial registration with no results posted; outcomes remain unknown and cannot be assessed.
Reported
Estimated enrollment68
Study phasePHASE 2
Primary outcome measureMajor Pathologic response (MPR), up to 1 ye…